Bill Vincent is a trained bioscientist, with a degree in Biology and Chemistry from Missouri State University and an MBA from the University of Texas at Austin. In his duties for Genezen, he serves as the company’s CEO and chief project manager, managing all progress of the contract manufacturing and clinical trials being done for clients.

He has turned his mix of experience in science and business into a life of entrepreneurial endeavors. Most recently, he is the president of two biotech companies, Genzen, and Rimedion, which currently has an NIH grant to study a new genetic therapy for orphan disease Fanconi Anemia. In previous positions, he has also served as operations supervisor at Abbot Labs, director of New Technology at Medical Automation Systems, and a consultant at Business Consulting company The Acacia Group.

Dr. Kenneth Cornetta Serves as the Clinical Director of Genezen. He is the Professor of Medicine, Microbiology/Immunology, and Medical and Molecular Genetics at Indiana University.

• B.S. 1978 - State University of New York; Albany NY
• M.D. 1982 - Albany Medical College; Albany, NY
• Internal Medicine Residency 1982-85, Indiana University
• Chief Medical Resident 1985-86, Indiana University
• NRSA Fellow, NHLBI, NIH 1986-89. Lab of Dr. W, French Anderson
Hematology Fellow, 1989-91. University of Wisconsin